Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07241949 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

External Oblique Intercostal Block (EOICB) for Laparoscopic Cholecystectomy

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title expanded, about 2 wordsv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary completion date: Jun 1, 2026 to Nov 1, 2026
    • Study completion date: Jun 5, 2026 to Dec 5, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description shortened, about 145 words
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This single-center, prospective, randomized controlled trial aims to compare the effects of paravertebral block (PVB), external oblique intercostal (EOI) block, and intravenous patient-controlled analgesia (PCA) with tramadol on postoperative pain and opioid consumption in patients undergoing elective laparoscopic cholecystectomy. The primary endpoint is total tramadol consumption within 24 hours postoperatively. Secondary outcomes include pain scores, additional analgesic use, incidence of nausea/vomiting, mobilization time, and length of hospital stay.
Trial Details
NCT Number NCT07241949
Lead Sponsor Cukurova University
Conditions
(from sponsor)		 Postoperative Pain, Laparoscopic Cholecystectomy, Paravertebral Block, External Oblique Intercostal Plane Block, Patient Controlled Analgesia
Related terms Agnosia, Pain, Postoperative Pain
Enrollment 147 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov